US Patent 7595303 Genetic adjuvants for immunotherapy
Patent 7595303 was granted and assigned to University of South Florida on September, 2009 by the United States Patent and Trademark Office.
All edits
The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (IL-12), interferon-gamma (IFN-γ), or a combination thereof, to a patient in need of such treatment. The pharmaceutical compositions of the invention contain nucleic acid molecules encoding IL-12 and/or IFN-γ and an operably-linked promoter sequence. In another aspect, the present invention concerns expression vectors containing a nucleotide sequence encoding IL-12 and IFN-γ, and an operably-linked promoter sequence. In another aspect, the present invention concerns cells generally modified with a nucleotide sequence encoding IL-12 and IFN-γ.
US Patent 07595303 Genetic adjuvants for immunotherapy US Patent 7595303 Genetic adjuvants for immunotherapy
US Patent 07595303 Genetic adjuvants for immunotherapy
Find more entities like US Patent 7595303 Genetic adjuvants for immunotherapy
